Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats

Diabetes

Volumn 60, Issue 5, 2011, Pages 1590-1598

  Clermont, Allen ^a,b   Chilcote, Tamie J ^c   Kita, Takeshi ^a,b   Liu, Jia ^a,b   Riva, Priscilla ^a   Sinha, Sukanto ^c   Feener, Edward P ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Activesite Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASP 440; COMPLEMENT COMPONENT C1S INHIBITOR; PLASMA KALLIKREIN; SERINE PROTEINASE INHIBITOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT; RETINA BLOOD FLOW; RETINA BLOOD VESSEL; RETINA THICKENING; RETINA VASCULAR DYSFUNCTION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STREPTOZOCIN DIABETES; THICKNESS;

ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME INHIBITORS; FLUORESCEIN ANGIOGRAPHY; FLUOROPHOTOMETRY; HEMODYNAMICS; HUMANS; MALE; PLASMA KALLIKREIN; RATS; RATS, SPRAGUE-DAWLEY; RETINA;

EID: 79959461744     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1260     Document Type: Article

References (39)

1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815 (Pubitemid 28509717)
2. Henricsson M, Sellman A, Tyrberg M, Groop L. Progression to proliferative retinopathy and macular oedema requiring treatment: assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand 1999;77:218-223 (Pubitemid 29164066)
3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298:902-916 (Pubitemid 47311296)
4. Elman MJ, Aiello LP, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.e35
5. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol 2004;137:313-322 (Pubitemid 38221006)
6. Antonetti DA, Barber AJ, Bronson SK, et al.; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411
7. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 2008;7:2516-2525
8. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007;13:181-188
9. Phipps JA, Feener EP. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int 2008;73:1114-1119 (Pubitemid 351620440)
10. Feener EP. Plasma kallikrein and diabetic macular edema. Curr Diab Rep 2010;10:270-275
11. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006;95:1003-1010 (Pubitemid 43933758)
12. Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol 2005;86:159-208 (Pubitemid 40215693)
13. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-1156
14. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057-1063 (Pubitemid 34408580)
15. Ma JX, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res 1996;63:19-26 (Pubitemid 26258796)
16. Yasuyoshi H, Kashii S, Zhang S, et al. Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest Ophthalmol Vis Sci 2000;41:2273-2278 (Pubitemid 30451003)
17. Abdouh M, Talbot S, Couture R, Hasséssian HM. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors. Br J Pharmacol 2008;154:136-143 (Pubitemid 351620390)
18. Jeppesen P, Aalkjaer C, Bek T. Bradykinin relaxation in small porcine retinal arterioles. Invest Ophthalmol Vis Sci 2002;43:1891-1896 (Pubitemid 34587037)
19. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 2009;53:175-181
20. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001;42:789-794 (Pubitemid 32206923)
21. Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997;38:2711-2720 (Pubitemid 28009392)
22. Horio N, Clermont AC, Abiko A, et al. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 2004;47:113-123
23. Ravindran S, Grys TE, Welch RA, Schapira M, Patston PA. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the aminoterminal domain of C1-inhibitor. Thromb Haemost 2004;92:1277-1283 (Pubitemid 39642537)
24. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997;46:1473-1480 (Pubitemid 27369086)
25. Lawson SR, Gabra BH, Guérin B, et al. Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist. Regul Pept 2005;124:221-224 (Pubitemid 39488363)
26. Abdouh M, Khanjari A, Abdelazziz N, Ongali B, Couture R, Hasséssian HM. Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br J Pharmacol 2003;140:33-40 (Pubitemid 37175828)
27. Kedzierska K, Ciechanowski K, Go?embiewska E, et al. Plasma prekallikrein as a risk factor for diabetic retinopathy. Arch Med Res 2005;36:539-543 (Pubitemid 41140062)
28. Tschöpe C, Reinecke A, Seidl U, et al. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. Am J Physiol 1999;277:H2333-H2340 (Pubitemid 30048154)
29. Sharma JN, Kesavarao U. Changes in plasma prekallikrein activity, blood pressure, and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmacol 2007;29:75-78 (Pubitemid 46797625)
30. Lawson SR, Gabra BH, Nantel F, Battistini B, Sirois P. Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs. Eur J Pharmacol 2005;514:69-78 (Pubitemid 40692765)
31. Bursell SE, Clermont AC, Aiello LP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245-1251 (Pubitemid 29350231)
32. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser doppler velocimetry study. Invest Ophthalmol Vis Sci 2010;51:6729-6734
33. Burgansky-Eliash Z, Nelson DA, Bar-Tal OP, Lowenstein A, Grinvald A, Barak A. Reduced retinal blood flow velocity in diabetic retinopathy. Retina 2010;30:765-773
34. Harpel PC. Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system. J Clin Invest 1972;51:1813-1822
35. Schousboe I, Nystrøm B. High molecular weight kininogen binds to laminin: characterization and kinetic analysis. FEBS J 2009;276:5228-5238
36. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-3218
37. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 2002;99:896-900 (Pubitemid 34106607)
38. Liu J, Gao BB, Feener EP. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome. Transl Stroke Res 2010;1:276-286
39. Yeung L, Lima VC, Garcia P, Landa G, Rosen RB. Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema. Ophthalmology 2009;116: 1158-1167